The ABTA surveyed patients, caregivers and physicians on the diagnosis and treatment of brain metastases and found disparities in care and communication. Published in the journey Neuro-Oncology Practice, this data highlight the needs of metastatic brain tumor patients.
About Meet Hope Head On
Because of the generous support from people like you, the ABTA has given over $35 million for brain tumor research. The ABTA’s campaign, “Meet Hope Head On,” created for our 50th anniversary, is focused on raising $50 million, in part to fund critical brain tumor research. This campaign is vital for continuing the kind of work that led to the recent FDA approval of vorasidenib, a breakthrough treatment for low-grade glioma.
